Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 28, 2026, 3:59 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Experimental Product 1 Clear all
Active, not recruiting Phase 2 Interventional

A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Sclerosing Cholangitis (PSC)

NCT04663308
View directory record Official record
Conditions
Primary Sclerosing Cholangitis
Interventions
Volixibat, Placebo
Drug
Lead sponsor
Mirum Pharmaceuticals, Inc.
Industry
Eligibility
12 Years and older
Enrollment
182 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
34
States / cities
Coronado, California • Los Angeles, California • Sacramento, California + 26 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Sep 28, 2026, 3:59 PM EDT
Terminated Phase 1 Interventional

Study of MGY825 in Patients With Advanced Non-small Cell Lung Cancer

NCT05275868
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
MGY825
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
7
States / cities
Boston, Massachusetts • St Louis, Missouri • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Sep 28, 2026, 3:59 PM EDT
Completed Phase 1 Interventional Results available

A Pilot Study of Moderate Hyperbilirubinemia in Type 1 Diabetes Mellitus

NCT01421355
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Atazanavir
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 20, 2014 · Synced Sep 28, 2026, 3:59 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Aging Program Project Grant 6

NCT03490825
View directory record Official record
Conditions
Improving Cardiometabolic Outcomes in Older Adults
Interventions
Melatonin 1 mg, Placebos, Meal timing, Non-Meal timing
Dietary Supplement · Other
Lead sponsor
Northwestern University
Other
Eligibility
55 Years to 75 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2024
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 22, 2025 · Synced Sep 28, 2026, 3:59 PM EDT
Active, not recruiting Phase 2 Interventional

Ribociclib (LEE011) Rollover Study for Continued Access

NCT02934568
View directory record Official record
Conditions
Continued Access to Study Treatment(s), Cancers With a Mass, Bulky Tumor, Nodule, Lump, Advanced Cancer, Advanced Solid Tumors, Advanced Solid Malignancies
Interventions
LEE011
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
0 Years to 80 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
5
States / cities
Birmingham, Alabama • Boston, Massachusetts • Ann Arbor, Michigan + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 15, 2026 · Synced Sep 28, 2026, 3:59 PM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate Safety and Efficacy of PF-06826647 For Moderate To Severe Plaque Psoriasis

NCT03895372
View directory record Official record
Conditions
Psoriasis
Interventions
PF-06826647 or Placebo, PF-06826647
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 75 Years
Enrollment
179 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
24
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Anaheim, California + 13 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2021 · Synced Sep 28, 2026, 3:59 PM EDT
Completed Phase 2 Interventional Results available

LIFT Study: A Safety, Tolerability, Efficacy, and Pharmacokinetics Study of TERN-101 in Subjects With Non-Cirrhotic Non-Alcoholic Steatohepatitis (NASH)

NCT04328077
View directory record Official record
Conditions
NASH - Nonalcoholic Steatohepatitis
Interventions
TERN-101, Placebo
Drug · Other
Lead sponsor
Terns, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years to 75 Years
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
31
States / cities
Chandler, Arizona • Tucson, Arizona • Coronado, California + 23 more
Source: ClinicalTrials.gov public record
Updated Aug 8, 2022 · Synced Sep 28, 2026, 3:59 PM EDT
Recruiting Phase 2 Interventional

A Study of Enzalutamide Plus the Glucocorticoid Receptor Antagonist Relacorilant Versus Placebo for Patients With High-risk Localized Prostate Cancer

NCT05726292
View directory record Official record
Conditions
Prostate Cancer, Prostate Adenocarcinoma
Interventions
Relacorilant, Enzalutamide, Placebo (Sugar Pill), Androgen Deprivation Therapy, Radical Prostatectomy
Drug · Other · Procedure
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older · Male only
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
4
States / cities
Chicago, Illinois • Evanston, Illinois • Portland, Oregon + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 30, 2026 · Synced Sep 28, 2026, 3:59 PM EDT
Terminated Phase 2 Interventional Results available

Penn Microbiome Therapy (PMT) for Severe-Clostridium Difficile Infection (CDI)

NCT03970200
View directory record Official record
Conditions
Severe Clostridium Difficile Infection, Severe-Complicated/Fulminant Clostridium Difficile Infection
Interventions
Penn Microbiome Therapy - 001, Penn Microbiome Therapy - 002, Penn Microbiome Therapy - 003, Antibiotics
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 29, 2023 · Synced Sep 28, 2026, 3:59 PM EDT
Recruiting Phase 1Phase 2 Interventional

A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast Cancer

NCT06827236
View directory record Official record
Conditions
Locally Advanced Breast Cancer, Unresectable Breast Carcinoma, Metastatic Breast Cancer
Interventions
BNT323, BNT327
Drug
Lead sponsor
BioNTech SE
Industry
Eligibility
18 Years and older
Enrollment
380 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
27
States / cities
Beverly Hills, California • Newport Beach, California • Port Saint Lucie, Florida + 18 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2026 · Synced Sep 28, 2026, 3:59 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Compare the Pharmacokinetics (PK) of Single Subcutaneous (SC) Injections of Vedolizumab Administered in Prefilled Syringe (PFS) Versus (vs) Prefilled Syringe in Autoinjector (PFS+AI) in Healthy Participants

NCT03961308
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Vedolizumab SC
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 65 Years
Enrollment
204 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
2
States / cities
Tempe, Arizona • Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Nov 13, 2019 · Synced Sep 28, 2026, 3:59 PM EDT
Completed Phase 2 Interventional

Study of the Safety and Neuroprotective Capacity of Scp776 in Acute Ischemic Stroke

NCT05585606
View directory record Official record
Conditions
Acute Ischemic Stroke (AIS)
Interventions
Placebo, scp776 (1.9 mg/kg), scp776 (3.8 mg/kg), scp776 (4.8 mg/kg), scp776 (all dose levels)
Drug
Lead sponsor
Silver Creek Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
22
States / cities
Scottsdale, Arizona • Tucson, Arizona • Hartford, Connecticut + 18 more
Source: ClinicalTrials.gov public record
Updated Feb 23, 2026 · Synced Sep 28, 2026, 3:59 PM EDT
Terminated Phase 1 Interventional

A Study of exoASO-STAT6 (CDK-004) in Patients With Advanced Hepatocellular Carcinoma (HCC) and Patients With Liver Metastases From EIther Primary Gastric Cancer or Colorectal Cancer (CRC)

NCT05375604
View directory record Official record
Conditions
Advanced Hepatocellular Carcinoma (HCC), Gastric Cancer Metastatic to Liver, Colorectal Cancer Metastatic to Liver
Interventions
CDK-004
Drug
Lead sponsor
Codiak BioSciences
Industry
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
3
States / cities
Duarte, California • New York, New York • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 31, 2023 · Synced Sep 28, 2026, 3:59 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of LY03015 in Healthy Chinese and Caucasian Adult Subjects

NCT07671833
View directory record Official record
Conditions
Healthy Participants
Interventions
LY03015 (LPM3770164 extended-release tablets)
Drug
Lead sponsor
Luye Pharma Group Ltd.
Industry
Eligibility
18 Years to 45 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Los Alamitos, California
Source: ClinicalTrials.gov public record
Updated Jun 25, 2026 · Synced Sep 28, 2026, 3:59 PM EDT
Completed Phase 2 Interventional

AD816 Crossover Study

NCT05793684
View directory record Official record
Conditions
OSA, Obstructive Sleep Apnea
Interventions
Period A, Period B, Period C
Drug
Lead sponsor
Apnimed
Industry
Eligibility
18 Years to 75 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
3
States / cities
Los Angeles, California • Boston, Massachusetts • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Nov 14, 2023 · Synced Sep 28, 2026, 3:59 PM EDT
Completed Phase 1Phase 2 Interventional

Study of Gene Therapy Using a Lentiviral Vector to Treat X-linked Chronic Granulomatous Disease

NCT02234934
View directory record Official record
Conditions
Granulomatous Disease, Chronic, X-linked
Interventions
Lentiviral G1XCGD Gene Therapy
Biological
Lead sponsor
University of California, Los Angeles
Other
Eligibility
23 Months and older · Male only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2024
U.S. locations
3
States / cities
Los Angeles, California • Bethesda, Maryland • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 1, 2025 · Synced Sep 28, 2026, 3:59 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Abemaciclib + Nivolumab in Patients With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma That Progressed or Recurred Within Six Months After Platinum-based Chemotherapy

NCT03655444
View directory record Official record
Conditions
Head and Neck Squamous Cell Carcinoma
Interventions
Abemaciclib, Nivolumab, Tumor biopsy, Peripheral blood, EORTC QLQ-30
Drug · Procedure · Other
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Dec 2, 2020 · Synced Sep 28, 2026, 3:59 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers Results available

Single Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ST-2427

NCT04475198
View directory record Official record
Conditions
Acute, Post-operative Pain
Interventions
ST-2427, Placebo
Drug
Lead sponsor
SiteOne Therapeutics, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Aug 2, 2023 · Synced Sep 28, 2026, 3:59 PM EDT
Completed Phase 1 Interventional

A First-in-human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of DS-6051b

NCT02279433
View directory record Official record
Conditions
Solid Tumors
Interventions
DS6051b
Drug
Lead sponsor
Nuvation Bio Inc.
Industry
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
6
States / cities
Scottsdale, Arizona • Orange, California • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2025 · Synced Sep 28, 2026, 3:59 PM EDT
Completed Phase 1 Interventional

Effects of Triiodothyronine (T3) in Ischemic Heart Failure

NCT05384847
View directory record Official record
Conditions
Heart Failure
Interventions
Thyroid hormone T3, Control Group
Drug · Other
Lead sponsor
Emory University
Other
Eligibility
18 Years to 80 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
2
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Aug 3, 2026 · Synced Sep 28, 2026, 3:59 PM EDT
Completed Phase 1 Interventional

Study of DS-7080a for the Treatment of Macular Degeneration

NCT02530918
View directory record Official record
Conditions
Neovascular Age-Related Macular Degeneration, Diabetic Macular Edema
Interventions
DS-7080a, Ranibizumab
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
12
States / cities
Phoenix, Arizona • Arcadia, California • Beverly Hills, California + 9 more
Source: ClinicalTrials.gov public record
Updated May 8, 2018 · Synced Sep 28, 2026, 3:59 PM EDT
Terminated Phase 1 Interventional

A Study of bbT369 in Relapsed and/or Refractory B Cell Non-Hodgkin's Lymphoma (NHL)

NCT05169489
View directory record Official record
Conditions
Diffuse Large B Cell Lymphoma (DLBCL)
Interventions
bbT369
Biological
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
4
States / cities
Stanford, California • Denver, Colorado • Tampa, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2025 · Synced Sep 28, 2026, 3:59 PM EDT
Withdrawn Phase 2 Interventional

Combination of an Investigational Cannabinoid and Methadone for HIV-associated Neuropathy

NCT00723918
View directory record Official record
Conditions
HIV-associated Neuropathy, Polyneuropathy
Interventions
SAB378, methadone, SAB placebo, Methadone placebo
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
3
States / cities
San Diego, California • Brooklyn, New York • Rochester, New York
Source: ClinicalTrials.gov public record
Updated Feb 8, 2018 · Synced Sep 28, 2026, 3:59 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluation of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E2609 in Healthy Subjects and an Elderly Cohort

NCT01294540
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Drug: E2609, Placebo
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
30 Years to 85 Years
Enrollment
73 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Aug 28, 2013 · Synced Sep 28, 2026, 3:59 PM EDT